Program
Cannabidiol
Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.
Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.
Drug pageCannabidiol: every studyMany companies study it; this page follows only the 64 they lead. All 316 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticalsits history only | 315 open or running | phase 4since Oct 17, 2019 | Oct 7, 2010 | Aug 1, 2027phase 4 · NCT05044819 |
| INSYS Therapeuticsits history only | 50 open or running | phase 3since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Radius Pharmaceuticalsits history only | 50 open or running | phase 3since Jan 26, 2018 | Jul 22, 2016 | none ahead |
| Cardiol Therapeuticsits history only | 41 open or running | phase 3since Nov 2, 2020 | Nov 2, 2020 | none ahead |
| Pure Greenits history only | 40 open or running | phase 2since Sep 10, 2019 | Sep 10, 2019 | none ahead |
| Canopy Growthits history only | 30 open or running | phase 2since Aug 29, 2019 | Aug 29, 2019 | none ahead |
| Botanix Pharmaceuticalsits history only | 20 open or running | phase 2since Jun 19, 2018 | Jun 19, 2018 | none ahead |
| Stero Biotechsits history only | 20 open or running | phase 2since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Avecho Biotechnologyits history only | 11 open or running | phase 3since Apr 23, 2023 | Apr 23, 2023 | Sep 30, 2027phase 3 · NCT05840822 |
| Bod Australiaits history only | 10 open or running | phase 2since Dec 20, 2021 | Dec 20, 2021 | none ahead |
| dsm-firmenichits history only | 10 open or running | phase 1since Aug 20, 2024 | Aug 20, 2024 | none ahead |
| EmpowerPharmits history only | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
| Kalytera Therapeutics Israelits history only | 10 open or running | phase 2since Feb 10, 2019 | Feb 10, 2019 | none ahead |
| Laboratorio Elea Phoenixits history only | 11 open or running | phase 2since Sep 30, 2024 | Sep 30, 2024 | none ahead |
| Pure Green Pharmaceuticalsits history only | 10 open or running | phase 2since Mar 2, 2023 | Mar 2, 2023 | none ahead |
| Tiamat Australia Ptyits history only | 10 open or running | phase 1since Feb 14, 2025 | Feb 14, 2025 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Research UK and Benuvia Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 45 earlier studies, Mar 17, 2014 to Mar 11, 2022.
- Jun 9, 2016Named cannabidiolINNProposed as its International Nonproprietary Name in WHO's List 115 · before, GWP42003-P, GWP42003
- Mar 21, 2022Phase 1 study in Bone Diseases, MetabolicCanopy Growth · NCT05317013 · 2 enrolled · United States
- Aug 8, 2022Phase 2 study in PericarditisCardiol Therapeutics · NCT05494788 · 27 enrolled · United States
- Oct 26, 2022EmpowerPharm’s first study: phase 2 study in Phobia, SocialNew to EmpowerPharmEmpowerPharm · NCT05600114 · 239 enrolled · United States
- Dec 24, 2022Phase 2 study in Menstrual DiscomfortCanopy Growth · NCT05679830 · 33 enrolled · United States
- Mar 2, 2023Pure Green Pharmaceuticals’ first study: phase 2 study in Diabetic Peripheral Neuropathic PainNew to Pure Green PharmaceuticalsPure Green Pharmaceuticals · NCT05766969 · 52 enrolled · United States
- Apr 23, 2023Avecho Biotechnology’s first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Avecho BiotechnologyAvecho Biotechnology · NCT05840822 · 519 enrolled · Australia
- May 9, 2023Phase 4 study in SeizuresJazz Pharmaceuticals · NCT05864846 · 79 enrolled · United States, Canada, Poland and more
- Aug 20, 2024dsm-firmenich’s first study: phase 1 study in CBD PharmacokineticsNew to dsm-firmenichdsm-firmenich · NCT06578455 · 32 enrolled · Canada
- Sep 30, 2024Laboratorio Elea Phoenix’s first study: phase 2 study in Parkinson DiseaseNew to Laboratorio Elea PhoenixLaboratorio Elea Phoenix · NCT06629389 · 88 planned · Argentina
- Nov 25, 2024Phase 3 study in PericarditisCardiol Therapeutics · NCT06708299 · 110 planned · United States, Canada, Greece and more
- Feb 14, 2025Tiamat Australia Pty’s first study: phase 1 study in PharmacokineticsNew to Tiamat Australia PtyTiamat Australia Pty · NCT06854783 · 20 enrolled · Australia
- Nov 14, 2025Phase 1 study in SeizuresJazz Pharmaceuticals · NCT07233239 · 100 planned · United States
- Jul 20, 20262 phase 3 studiesJazz Pharmaceuticals · NCT07723976, NCT07723963
- Jul 22, 2026Phase 4 study in Lennox Gastaut SyndromeJazz Pharmaceuticals · NCT07728097 · 40 planned · United States
Ahead
- Aug 1, 2027Primary completion: phase 4 study in Lennox Gastaut SyndromeJazz Pharmaceuticals · NCT05044819
- Sep 30, 2027Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersAvecho Biotechnology · NCT05840822
- Nov 29, 2027Primary completion: phase 1 study in SeizuresJazz Pharmaceuticals · NCT07233239
- Aug 1, 2028Primary completion: phase 3 study in Myoclonic Epilepsy, JuvenileJazz Pharmaceuticals · NCT07723963
TargetBeta
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rimonabantrule | Sanofi | phase 3 | 39 |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 20 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07728097Lennox Gastaut Syndrome · United States | 4 | Not yet recruiting | Jazz Pharmaceuticals | Dec 28, 2028 | 40 |
| NCT07723976Developmental and Epileptic Encephalopathy (DEE) · United States, Australia, Hungary and more | 3 | Recruiting | Jazz Pharmaceuticals | Sep 4, 2029 | 120 |
| NCT07723963Myoclonic Epilepsy, Juvenile · United States | 3 | Recruiting | Jazz Pharmaceuticals | Aug 1, 2028 | 260 |
| NCT07233239Seizures · United States | 1 | Recruiting | Jazz Pharmaceuticals | Nov 29, 2027 | 100 |
| NCT06854783Pharmacokinetics · Australia | 1 | Completed | Tiamat Australia Pty | Oct 1, 2025 | 20 |
| NCT06708299Pericarditis · United States, Canada, Greece and more | 3 | Recruiting | Cardiol Therapeutics | Sep 21, 2026 | 110 |
| NCT06629389Parkinson Disease · Argentina | 2 | Recruiting | Laboratorio Elea Phoenix | Nov 2025 | 88 |
| NCT06578455CBD Pharmacokinetics · Canada | 1 | Completed | dsm-firmenich | Nov 20, 2024 | 32 |
| NCT05864846Seizures · United States, Canada, Poland and more | 4 | Completed | Jazz Pharmaceuticals | Apr 6, 2026 | 79 |
| NCT05840822Sleep Initiation and Maintenance Disorders · Australia | 3 | Active, not recruiting | Avecho Biotechnology | Sep 30, 2027 | 519 |
| NCT05766969Diabetic Peripheral Neuropathic Pain · United States | 2 | UNKNOWN | Pure Green Pharmaceuticals | Dec 5, 2023 | 52 |
| NCT05679830Menstrual Discomfort · United States | 2 | Completed | Canopy Growth | Sep 23, 2021 | 33 |
| NCT05600114Phobia, Social · United States | 2 | Completed | EmpowerPharm | Dec 13, 2023 | 239 |
| NCT05494788Pericarditis · United States | 2 | Completed | Cardiol Therapeutics | Jun 15, 2024 | 27 |
| NCT05317013Bone Diseases, Metabolic · United States | 1 | Terminated | Canopy Growth | Sep 22, 2022 | 2 |
| NCT05288283Epilepsy · United States, Italy | 3 | Terminated | Jazz Pharmaceuticals | Sep 28, 2023 | 3 |
| NCT05253417Parasomnias · Australia | 2 | Completed | Bod Australia | Jul 7, 2023 | 208 |
| NCT05180240Acute Myocarditis · United States, Brazil, Canada and more | 2 | Completed | Cardiol Therapeutics | Jan 31, 2025 | 109 |
| NCT05044819Lennox Gastaut Syndrome · United States | 4 | Active, not recruiting | Jazz Pharmaceuticals | Aug 1, 2027 | 154 |
| NCT04992962Osteoarthritis, Knee · United States | 2 | UNKNOWN | Pure Green | Oct 30, 2021 | 66 |
| NCT04745026Autism Spectrum Disorder · United States, Australia, Canada and more | 2 | Completed | Jazz Pharmaceuticals | Dec 21, 2023 | 103 |
| NCT04679545Diabetic Peripheral Neuropathic Pain · United States | 2 | UNKNOWN | Pure Green | Mar 1, 2021 | 50 |
| NCT04615949COVID-19 · United States, Brazil, Mexico | 3 | Terminated | Cardiol Therapeutics | Nov 30, 2022 | 90 |
| NCT04485104Epilepsy · United States, Italy, Spain | 3 | Terminated | Jazz Pharmaceuticals | Jan 28, 2025 | 3 |
| NCT04421456Schizophrenia · United States, Poland, Serbia and more | 2 | Terminated | Jazz Pharmaceuticals | Mar 16, 2022 | 95 |
| NCT04252586Rett Syndrome · United States, Australia, Canada and more | 3 | Terminated | Jazz Pharmaceuticals | Jun 9, 2021 | 21 |
| NCT04439955Chronic Urticaria · Israel | 2 | Completed | Stero Biotechs | Jul 30, 2021 | 15 |
| NCT04193631Musculoskeletal Pain · United States | 1 | Completed | Pure Green | Dec 9, 2019 | 16 |
| NCT04133480Lennox Gastaut Syndrome | 4 | Withdrawn | Jazz Pharmaceuticals | Dec 2021 | 0 |
| NCT04088929Diabetic Neuropathies · United States | 2 | Completed | Pure Green | Nov 22, 2019 | 32 |
| NCT04086342Phobia, Social · Canada | 2 | Withdrawn | Canopy Growth | Jan 26, 2021 | 0 |
| NCT04129489Hepatitis, Autoimmune · Israel | 2 | Terminated | Stero Biotechs | Mar 1, 2020 | 2 |
| NCT03848832Rett Syndrome · United States, Italy, Spain and more | 3 | Terminated | Jazz Pharmaceuticals | Jan 21, 2021 | 29 |
| NCT03840512Prevention aGVHD · Australia, Israel | 2 | UNKNOWN | Kalytera Therapeutics Israel | Nov 15, 2022 | 36 |
| NCT03824405Dermatitis, Atopic · United States, Australia, New Zealand | 2 | Completed | Botanix Pharmaceuticals | Jan 27, 2020 | 200 |
| NCT03573518Acne Vulgaris · United States, Australia | 2 | Completed | Botanix Pharmaceuticals | Aug 16, 2019 | 368 |
| NCT03458416Prader-Willi Syndrome · United States | 2 | Terminated | Radius Pharmaceuticals | Jul 31, 2019 | 2 |
| NCT03421496Spasms, Infantile · United States | 3 | Terminated | Radius Pharmaceuticals | May 29, 2019 | 2 |
| NCT03355300Epilepsy, Absence · United States | 2 | Terminated | Radius Pharmaceuticals | Jun 24, 2019 | 11 |
| NCT03336242Epilepsy, Absence · United States | 2 | Terminated | Radius Pharmaceuticals | May 15, 2019 | 20 |
| NCT02954887Spasms, Infantile · United States, Poland | 3 | Completed | Jazz Pharmaceuticals | Jun 13, 2019 | 9 |
| NCT02953548Spasms, Infantile · United States, Poland | 3 | Completed | Jazz Pharmaceuticals | May 7, 2018 | 9 |
| NCT02844933Prader-Willi Syndrome · United States | 2 | Terminated | Radius Pharmaceuticals | Jul 17, 2019 | 7 |
| NCT02607904Epilepsy · Netherlands, Spain, Sweden | 2 | Completed | Jazz Pharmaceuticals | May 27, 2019 | 30 |
| NCT02607891Epilepsy · Netherlands, Spain, Sweden | 2 | Completed | Jazz Pharmaceuticals | Sep 11, 2018 | 35 |
| NCT02565108Epilepsy · Spain, United Kingdom | 2 | Completed | Jazz Pharmaceuticals | Jul 21, 2016 | 20 |
| NCT02564952Epilepsy · Spain, United Kingdom | 2 | Completed | Jazz Pharmaceuticals | Jun 7, 2017 | 18 |
| NCT02551731Spasms, Infantile · United States | 2 | Terminated | INSYS Therapeutics | Sep 6, 2016 | 9 |
| NCT02544763Tuberous Sclerosis · United States, Australia, Netherlands and more | 3 | Completed | Jazz Pharmaceuticals | Jan 22, 2019 | 224 |
| NCT02544750Tuberous Sclerosis · United States | 3 | Completed | Jazz Pharmaceuticals | Jun 11, 2021 | 199 |
| NCT02324673Seizures · United States | 2 | Completed | INSYS Therapeutics | May 9, 2016 | 61 |
| NCT02318602Seizures · United States | 3 | Completed | INSYS Therapeutics | Jun 22, 2017 | 52 |
| NCT02318563Epilepsies, Myoclonic | 3 | Withdrawn | INSYS Therapeutics | Jun 17, 2018 | 0 |
| NCT02318537Lennox Gastaut Syndrome | 3 | Withdrawn | INSYS Therapeutics | Jun 30, 2018 | 0 |
| NCT02224703Epilepsy · United States, Australia, Israel and more | 3 | Completed | Jazz Pharmaceuticals | Apr 9, 2018 | 199 |
| NCT02224690Epilepsy · United States, Netherlands, Poland | 3 | Completed | Jazz Pharmaceuticals | Mar 18, 2016 | 171 |
| NCT02224573Epilepsy | 3 | Completed | Jazz Pharmaceuticals | Sep 24, 2020 | 681 |
| NCT02224560Epilepsy · United States, France, Spain and more | 3 | Completed | Jazz Pharmaceuticals | May 19, 2016 | 225 |
| NCT02091375Epilepsy · United States, France, Poland and more | 3 | Completed | Jazz Pharmaceuticals | Nov 26, 2015 | 120 |
| NCT02091206Epilepsy · United States, United Kingdom | 2 | Completed | Jazz Pharmaceuticals | Mar 9, 2015 | 34 |
How it is read
Names in the registry
- “GWP42003-P”, 17 entries
- “Cannabidiol Oral Solution”, 10 entries
- “Cannabidiol”, 7 entries
- “CBD”, 5 entries
- “GWP42003”, 4 entries
Codes read as this program: JZP926.
Conditions, from the studies’ own filings
- Epilepsy, 7 studies
- Lennox Gastaut Syndrome, 6 studies
- Epilepsies, Myoclonic, 5 studies
- Seizures, 4 studies
- Spasms, Infantile, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.